Prevalence of cardiovascular risk factors in patients with psoriatic arthritis

Abstract

Psoriatic arthritis (PsA) is a chronic T cell-mediated inflammatory spondyloarthropathy affecting 10-40 % of psoriasis (PSO) patients (0.3-1.0 % of the general population). Recent epidemiological studies have shown an increased prevalence of cardiovascular (CV) risk factors and/or morbidity among PSO or PsA patients as compared to control individuals. The aim of this study is to describe the CV profile of PsA patients in Newfoundland, Canada. The possible impact of duration of chronic inflammation on CV variables was also explored. PsA patients were selected from a registry of PSO and PsA patients in Newfoundland. PsA patients diagnosed as per the CASPAR criteria are entered in the registry at the time of diagnosis, questioned on their medical history, and are followed indefinitely. Based on the duration since PsA diagnosis patients were classified as having early (<2 years) or established (≥2 years) PsA. CV risk was assessed using both conventional (hypertension, hypercholesterolemia, diabetes, obesity) and non-conventional (markers of chronic inflammation) factors. A total of 196 PsA patients were included; 42.9 % had early PsA and 57.1 % had established PsA. The prevalence of hypercholesterolemia, obesity, hypertension, diabetes mellitus, anxiety/depression, and coronary heart disease was 61.6, 59.7, 32.7, 13.8, 13.8, and 8.7 %, respectively. The prevalence of comorbidities was generally comparable between cohorts with exception of anxiety/depression, which was considerably higher in patients with established PsA compared to early PsA and obesity which was more common among male patients with established PsA. However, upon adjusting for age and gender differences, no statistically significant between-group differences were observed. Overall, these results suggest that PsA, even at early stages, is associated with significant CV comorbidity. These conditions should be taken into consideration when assessing the PsA burden of illness in epidemiological and health outcomes studies. Furthermore, early detection and management of these conditions could improve the patients' disability and quality of life.

Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study

“…Nonetheless, these mechanisms together create a classic downward spiral. At present, close monitoring and preventive measures for various comorbidities including, but not restricted to, cardiovascular diseases should be undertaken when dealing with patients with PsA in the clinic 28 29. Moreover, early diagnosis and sufficient and aggressive treatment, including antitumour necrosis factor therapy, seems to have an impact on the risk for developing work disability and thus diminishing the burden of disease from a patient's perspective and societal perspective 10 24 30.…”

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

“…The prevalence of PsA is 0.3-1.0% in the general population and around 10-40% of psoriasis patients will develop PsA in their lifetime [1][2][3][4][5]. Disease severity varies amongst individuals and can range from mild swelling and inflammation to joint incapacitation.…”

Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis

“…41 As befits a condition grouped with other spondyloarthropathies, an increased prevalence of inflammatory bowel disease, either overt or covert, is observed. Finally, psychological morbidity is increased in psoriatic arthritis, particularly depression, an increase shared with psoriasis.…”